Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allografts Clear all
Completed Not applicable Interventional Results available

Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy

NCT01078363
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
ramipril, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 21, 2026, 1:43 PM EDT
Completed No phase listed Observational

The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation

NCT00056784
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Influence of Bone Allograft Particle Sizes on the Quantity and Quality of New Bone Formation in Grafted Extraction Sockets and Edentulous Ridges

NCT03468998
View directory record Official record
Conditions
Alveolar Ridge Augmentation, Alveolar Ridge Preservation
Interventions
Socket Grafting with small particle allograft, Socket Grafting with large particle allograft, Lateral ridge augmentation with small particle allograft, Lateral ridge augmentation with large particle allograft
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

NCT01168219
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine, Busulfan, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Pharmacological Study, Tacrolimus
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 74 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
17
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 21, 2026, 1:43 PM EDT
Withdrawn Not applicable Interventional

Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients

NCT01812434
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

NCT00014235
View directory record Official record
Conditions
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies, Waldenström Macroglobulinemia
Interventions
fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 74 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
9
States / cities
Tucson, Arizona • Duarte, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 4 Interventional

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

NCT00363116
View directory record Official record
Conditions
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Interventions
Daclizumab
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
23
States / cities
Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 4 Interventional

Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts

NCT00374647
View directory record Official record
Conditions
Primary Renal Allograft
Interventions
mycophenolate mofetil, sirolimus
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 21, 2026, 1:43 PM EDT
Completed No phase listed Observational

Clinical Trial to Examine Effectiveness of a Human Allograft for Treatment of DFU and VLU

NCT03999281
View directory record Official record
Conditions
Determine Effectiveness of Theraskin in the Treatment of DFU and VLU
Interventions
Human Allograft (Theraskin)
Other
Lead sponsor
Solsys Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Timeline
2003 – 2009
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 21, 2026, 1:43 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of a Composite Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Knee Osteochondral Defects

NCT00984594
View directory record Official record
Conditions
Knee Injury
Interventions
Primary injury site, Backfill site
Other
Lead sponsor
RTI Surgical
Industry
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 21, 2026, 1:43 PM EDT
Not yet recruiting Phase 1 Interventional

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT07737769
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection, Bone Marrow Biopsy, Busulfan, Fludarabine
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant

NCT00092937
View directory record Official record
Conditions
Granulomatous Disease, Chronic
Interventions
Busulfan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

NCT00350818
View directory record Official record
Conditions
Myelodysplastic Syndrome, Leukemia
Interventions
Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 21, 2026, 1:43 PM EDT
Withdrawn No phase listed Observational

Noninvasive Predictors of Transplant Vasculopathy

NCT01424917
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 21, 2026, 1:43 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Axis(TM) Solvent-dehydrate Dermal Allograft in the Treatment of Pelvic Organ Prolapse.

NCT06263985
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Axis Dermis biologic mesh repair for pelvic organ prolapse
Device
Lead sponsor
Michigan Institution of Women's Health PC
Other
Eligibility
21 Years to 89 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

NCT00807794
View directory record Official record
Conditions
Kidney Diseases
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
4
States / cities
New Haven, Connecticut • Bloomington, Indiana • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2008 · Synced Oct 21, 2026, 1:43 PM EDT
Not listed Not applicable Interventional

BMAC Nerve Allograft Study

NCT03964129
View directory record Official record
Conditions
Peripheral Nerve Injury Upper Limb
Interventions
Avance Nerve Graft with Autologous BMAC
Procedure
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 74 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Results available

Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

NCT01327573
View directory record Official record
Conditions
Kidney; Complications, Allograft
Interventions
eculizumab
Drug
Lead sponsor
Sanjay Kulkarni
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

NCT00506129
View directory record Official record
Conditions
Lymphoma, Disorder Related to Bone Marrow Transplantation
Interventions
Fludarabine, Melphalan, Allogeneic Transplant, Thymoglobulin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

NCT01010217
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
Interventions
Cyclophosphamide, Fludarabine, Melphalan, Mesna, Rituximab, Stem Cell Transplantation, Thiotepa, Tacrolimus, Mycofenolate mofetil, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Belatacept Conversion in Proteinuric Kidney Transplant Recipients

NCT02327403
View directory record Official record
Conditions
Proteinuria
Interventions
Belatacept
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 21, 2026, 1:43 PM EDT
Terminated Not applicable Interventional Results available

Human Amniotic Tissue-derived Allograft, NuCel, in Posteriolateral Lumbar Fusions for Degenerative Disc Disease

NCT02070484
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis, Spondylosis, Intervertebral Disk Displacement, Intervertebral Disk Degeneration, Spinal Diseases, Bone Diseases, Musculoskeletal Diseases, Spondylolysis
Interventions
NuCel, Demineralized Bone Matrix
Biological
Lead sponsor
OhioHealth
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 21, 2026, 1:43 PM EDT
Recruiting Phase 3 Interventional

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 1:43 PM EDT
Not listed Not applicable Interventional

Hand Ligament Reconstructions With Knee Collateral Ligament Allografts

NCT05060900
View directory record Official record
Conditions
Hand Injuries, Wrist Injuries, Ligament Injury, Ligament Rupture, Ligament Avulsion
Interventions
Ligament Reconstruction with Allograft Ligament
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 21, 2026, 1:43 PM EDT